Abstract Details

Title 24-Month Efficacy and Safety Outcomes from the TRANSFORMS Extension Study of Oral Fingolimod (FTY720) in Patients with Relapsing-Remitting Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 125

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
	No disclosure on file
	No disclosure on file
Frederick Holdbrook	Frederick Holdbrook has received personal compensation for serving as an employee of Amicus Therapeutics, Inc. Frederick Holdbrook has stock in Amicus Therapeutics, Inc.

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��